Combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin against murine and human tumors in vivo
The in vivo combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin (CDDP) was examined. The combination of AC‐7700 and CDDP increased antitumor activity against murine colon 26 tumor in mice and cured the mice. This combination effect was found over wide dosage ranges of...
Gespeichert in:
| Veröffentlicht in: | Cancer science 2003-02, Vol.94 (2), p.200-204 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 204 |
|---|---|
| container_issue | 2 |
| container_start_page | 200 |
| container_title | Cancer science |
| container_volume | 94 |
| creator | Morinaga, Yoshihiro Suga, Yasuyo Ehara, Sumiko Harada, Katsuhiro Nihei, Yukio Suzuki, Manabu |
| description | The in vivo combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin (CDDP) was examined. The combination of AC‐7700 and CDDP increased antitumor activity against murine colon 26 tumor in mice and cured the mice. This combination effect was found over wide dosage ranges of AC‐7700 (20–80 mg/kg) and CDDP (2.5–5 mg/kg). Moreover, this combination augmented antitumor activity against murine S180 and M109 tumors, and human LX‐1 and LS180 tumor xenografts in mice. The effect was the strongest when AC‐7700 and CDDP were administered simultaneously. To study this combination effect we measured the concentrations of CDDP in tumors, plasma and kidneys of the mice with colon 26 tumor. In the combination with AC‐7700, the concentration of CDDP in the tumors increased from 0.5 to 96 h after administration, but did not change or decrease in plasma or kidneys. Against human LS180 xenografts in mice, the combination similarly increased the concentration of CDDP in the tumors. These results suggest that AC‐7700 may specifically augment the accumulation of CDDP in tumors, and thus has the potential to be useful in combination chemotherapy with CDDP. (Cancer Sci 2003; 94: 200–204) |
| doi_str_mv | 10.1111/j.1349-7006.2003.tb01419.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11160070</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2399349524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5890-25b94b3bbb82020dfad57e20c4a679b8a23c73b49ae2b768cbcc5ddd3bc6d7533</originalsourceid><addsrcrecordid>eNqVkctu1DAYhSMEohd4BWSB6IoE3xLHXYBGETepEgtgbdmO03qU2IOdhHYFj8Az8iQ4M1EL7PDGl_P9x_59suwpggVK4-W2QITynEFYFRhCUowKIop4cX0vO76V7u_XLOeQ4KPsJMZtQivK6cPsCGEGa8rZcfa98YOyTo7WO2C6zugR-A5sml8_frJk8wJI4PxseqATGMwo45hgBzYJoKA1wc5pP5sEuhZoG3f9XpeX0ro4gmEK1pm9eDUN0oFxGnyIICGznf2j7EEn-2ger_Np9uXtm8_N-_zi47sPzeYi12XNYY5LxakiSqkaQwzbTrYlMxhqKivGVS0x0YwoyqXBilW1VlqXbdsSpauWlYScZq8PvrtJDabVxo1B9mIX7CDDjfDSir8VZ6_EpZ9F-vAKQgaTw9nqEPzXycRRDDZq0_fSGT9FwQhGtKZ1Ap_9A279FFzqTmDCecqnxDRR5wdKBx9jMN3tWxBcLkViK5YsxZKlWGIWa8ziOhU_-bObu9I11wQ8XwEZtey7IF2K5o4rcYUQX5p6deC-2d7c_McTRLP5tJz8Bnusx9g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399349524</pqid></control><display><type>article</type><title>Combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin against murine and human tumors in vivo</title><source>Wiley Online Library Open Access</source><creator>Morinaga, Yoshihiro ; Suga, Yasuyo ; Ehara, Sumiko ; Harada, Katsuhiro ; Nihei, Yukio ; Suzuki, Manabu</creator><creatorcontrib>Morinaga, Yoshihiro ; Suga, Yasuyo ; Ehara, Sumiko ; Harada, Katsuhiro ; Nihei, Yukio ; Suzuki, Manabu</creatorcontrib><description>The in vivo combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin (CDDP) was examined. The combination of AC‐7700 and CDDP increased antitumor activity against murine colon 26 tumor in mice and cured the mice. This combination effect was found over wide dosage ranges of AC‐7700 (20–80 mg/kg) and CDDP (2.5–5 mg/kg). Moreover, this combination augmented antitumor activity against murine S180 and M109 tumors, and human LX‐1 and LS180 tumor xenografts in mice. The effect was the strongest when AC‐7700 and CDDP were administered simultaneously. To study this combination effect we measured the concentrations of CDDP in tumors, plasma and kidneys of the mice with colon 26 tumor. In the combination with AC‐7700, the concentration of CDDP in the tumors increased from 0.5 to 96 h after administration, but did not change or decrease in plasma or kidneys. Against human LS180 xenografts in mice, the combination similarly increased the concentration of CDDP in the tumors. These results suggest that AC‐7700 may specifically augment the accumulation of CDDP in tumors, and thus has the potential to be useful in combination chemotherapy with CDDP. (Cancer Sci 2003; 94: 200–204)</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/j.1349-7006.2003.tb01419.x</identifier><identifier>PMID: 12708497</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - pathology ; Animals ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Antitumor activity ; Biological and medical sciences ; Body Weight - drug effects ; Chemotherapy ; Cisplatin ; Cisplatin - administration & dosage ; Cisplatin - pharmacokinetics ; Colon ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - pathology ; Drug Administration Schedule ; Humans ; Kidneys ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Medical sciences ; Mice ; Mice, Inbred ICR ; Mice, Nude ; Pharmacology. Drug treatments ; Sarcoma 180 - drug therapy ; Serine - administration & dosage ; Serine - analogs & derivatives ; Serine - pharmacokinetics ; Tumor Cells, Cultured - drug effects ; Tumors ; Xenograft Model Antitumor Assays ; Xenografts</subject><ispartof>Cancer science, 2003-02, Vol.94 (2), p.200-204</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright John Wiley & Sons, Inc. Feb 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5890-25b94b3bbb82020dfad57e20c4a679b8a23c73b49ae2b768cbcc5ddd3bc6d7533</citedby><cites>FETCH-LOGICAL-c5890-25b94b3bbb82020dfad57e20c4a679b8a23c73b49ae2b768cbcc5ddd3bc6d7533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160070/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160070/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1349-7006.2003.tb01419.x$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15261190$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12708497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morinaga, Yoshihiro</creatorcontrib><creatorcontrib>Suga, Yasuyo</creatorcontrib><creatorcontrib>Ehara, Sumiko</creatorcontrib><creatorcontrib>Harada, Katsuhiro</creatorcontrib><creatorcontrib>Nihei, Yukio</creatorcontrib><creatorcontrib>Suzuki, Manabu</creatorcontrib><title>Combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin against murine and human tumors in vivo</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>The in vivo combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin (CDDP) was examined. The combination of AC‐7700 and CDDP increased antitumor activity against murine colon 26 tumor in mice and cured the mice. This combination effect was found over wide dosage ranges of AC‐7700 (20–80 mg/kg) and CDDP (2.5–5 mg/kg). Moreover, this combination augmented antitumor activity against murine S180 and M109 tumors, and human LX‐1 and LS180 tumor xenografts in mice. The effect was the strongest when AC‐7700 and CDDP were administered simultaneously. To study this combination effect we measured the concentrations of CDDP in tumors, plasma and kidneys of the mice with colon 26 tumor. In the combination with AC‐7700, the concentration of CDDP in the tumors increased from 0.5 to 96 h after administration, but did not change or decrease in plasma or kidneys. Against human LS180 xenografts in mice, the combination similarly increased the concentration of CDDP in the tumors. These results suggest that AC‐7700 may specifically augment the accumulation of CDDP in tumors, and thus has the potential to be useful in combination chemotherapy with CDDP. (Cancer Sci 2003; 94: 200–204)</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - pathology</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Antitumor activity</subject><subject>Biological and medical sciences</subject><subject>Body Weight - drug effects</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - pharmacokinetics</subject><subject>Colon</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - pathology</subject><subject>Drug Administration Schedule</subject><subject>Humans</subject><subject>Kidneys</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred ICR</subject><subject>Mice, Nude</subject><subject>Pharmacology. Drug treatments</subject><subject>Sarcoma 180 - drug therapy</subject><subject>Serine - administration & dosage</subject><subject>Serine - analogs & derivatives</subject><subject>Serine - pharmacokinetics</subject><subject>Tumor Cells, Cultured - drug effects</subject><subject>Tumors</subject><subject>Xenograft Model Antitumor Assays</subject><subject>Xenografts</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqVkctu1DAYhSMEohd4BWSB6IoE3xLHXYBGETepEgtgbdmO03qU2IOdhHYFj8Az8iQ4M1EL7PDGl_P9x_59suwpggVK4-W2QITynEFYFRhCUowKIop4cX0vO76V7u_XLOeQ4KPsJMZtQivK6cPsCGEGa8rZcfa98YOyTo7WO2C6zugR-A5sml8_frJk8wJI4PxseqATGMwo45hgBzYJoKA1wc5pP5sEuhZoG3f9XpeX0ro4gmEK1pm9eDUN0oFxGnyIICGznf2j7EEn-2ger_Np9uXtm8_N-_zi47sPzeYi12XNYY5LxakiSqkaQwzbTrYlMxhqKivGVS0x0YwoyqXBilW1VlqXbdsSpauWlYScZq8PvrtJDabVxo1B9mIX7CDDjfDSir8VZ6_EpZ9F-vAKQgaTw9nqEPzXycRRDDZq0_fSGT9FwQhGtKZ1Ap_9A279FFzqTmDCecqnxDRR5wdKBx9jMN3tWxBcLkViK5YsxZKlWGIWa8ziOhU_-bObu9I11wQ8XwEZtey7IF2K5o4rcYUQX5p6deC-2d7c_McTRLP5tJz8Bnusx9g</recordid><startdate>200302</startdate><enddate>200302</enddate><creator>Morinaga, Yoshihiro</creator><creator>Suga, Yasuyo</creator><creator>Ehara, Sumiko</creator><creator>Harada, Katsuhiro</creator><creator>Nihei, Yukio</creator><creator>Suzuki, Manabu</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>John Wiley & Sons, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200302</creationdate><title>Combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin against murine and human tumors in vivo</title><author>Morinaga, Yoshihiro ; Suga, Yasuyo ; Ehara, Sumiko ; Harada, Katsuhiro ; Nihei, Yukio ; Suzuki, Manabu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5890-25b94b3bbb82020dfad57e20c4a679b8a23c73b49ae2b768cbcc5ddd3bc6d7533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - pathology</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Antitumor activity</topic><topic>Biological and medical sciences</topic><topic>Body Weight - drug effects</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - pharmacokinetics</topic><topic>Colon</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - pathology</topic><topic>Drug Administration Schedule</topic><topic>Humans</topic><topic>Kidneys</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred ICR</topic><topic>Mice, Nude</topic><topic>Pharmacology. Drug treatments</topic><topic>Sarcoma 180 - drug therapy</topic><topic>Serine - administration & dosage</topic><topic>Serine - analogs & derivatives</topic><topic>Serine - pharmacokinetics</topic><topic>Tumor Cells, Cultured - drug effects</topic><topic>Tumors</topic><topic>Xenograft Model Antitumor Assays</topic><topic>Xenografts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morinaga, Yoshihiro</creatorcontrib><creatorcontrib>Suga, Yasuyo</creatorcontrib><creatorcontrib>Ehara, Sumiko</creatorcontrib><creatorcontrib>Harada, Katsuhiro</creatorcontrib><creatorcontrib>Nihei, Yukio</creatorcontrib><creatorcontrib>Suzuki, Manabu</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Morinaga, Yoshihiro</au><au>Suga, Yasuyo</au><au>Ehara, Sumiko</au><au>Harada, Katsuhiro</au><au>Nihei, Yukio</au><au>Suzuki, Manabu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin against murine and human tumors in vivo</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2003-02</date><risdate>2003</risdate><volume>94</volume><issue>2</issue><spage>200</spage><epage>204</epage><pages>200-204</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>The in vivo combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin (CDDP) was examined. The combination of AC‐7700 and CDDP increased antitumor activity against murine colon 26 tumor in mice and cured the mice. This combination effect was found over wide dosage ranges of AC‐7700 (20–80 mg/kg) and CDDP (2.5–5 mg/kg). Moreover, this combination augmented antitumor activity against murine S180 and M109 tumors, and human LX‐1 and LS180 tumor xenografts in mice. The effect was the strongest when AC‐7700 and CDDP were administered simultaneously. To study this combination effect we measured the concentrations of CDDP in tumors, plasma and kidneys of the mice with colon 26 tumor. In the combination with AC‐7700, the concentration of CDDP in the tumors increased from 0.5 to 96 h after administration, but did not change or decrease in plasma or kidneys. Against human LS180 xenografts in mice, the combination similarly increased the concentration of CDDP in the tumors. These results suggest that AC‐7700 may specifically augment the accumulation of CDDP in tumors, and thus has the potential to be useful in combination chemotherapy with CDDP. (Cancer Sci 2003; 94: 200–204)</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>12708497</pmid><doi>10.1111/j.1349-7006.2003.tb01419.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1347-9032 |
| ispartof | Cancer science, 2003-02, Vol.94 (2), p.200-204 |
| issn | 1347-9032 1349-7006 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11160070 |
| source | Wiley Online Library Open Access |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - pathology Animals Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Biological and medical sciences Body Weight - drug effects Chemotherapy Cisplatin Cisplatin - administration & dosage Cisplatin - pharmacokinetics Colon Colonic Neoplasms - drug therapy Colonic Neoplasms - pathology Drug Administration Schedule Humans Kidneys Lung Neoplasms - drug therapy Lung Neoplasms - pathology Medical sciences Mice Mice, Inbred ICR Mice, Nude Pharmacology. Drug treatments Sarcoma 180 - drug therapy Serine - administration & dosage Serine - analogs & derivatives Serine - pharmacokinetics Tumor Cells, Cultured - drug effects Tumors Xenograft Model Antitumor Assays Xenografts |
| title | Combination effect of AC‐7700, a novel combretastatin A‐4 derivative, and cisplatin against murine and human tumors in vivo |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T14%3A57%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20effect%20of%20AC%E2%80%907700,%20a%20novel%20combretastatin%20A%E2%80%904%20derivative,%20and%20cisplatin%20against%20murine%20and%20human%20tumors%20in%20vivo&rft.jtitle=Cancer%20science&rft.au=Morinaga,%20Yoshihiro&rft.date=2003-02&rft.volume=94&rft.issue=2&rft.spage=200&rft.epage=204&rft.pages=200-204&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/j.1349-7006.2003.tb01419.x&rft_dat=%3Cproquest_24P%3E2399349524%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2399349524&rft_id=info:pmid/12708497&rfr_iscdi=true |